Fate Therapeutics Inc. (FATE)
NASDAQ: FATE
· Real-Time Price · USD
1.03
-0.07 (-6.36%)
At close: Jun 27, 2025, 3:59 PM
1.02
-1.45%
After-hours: Jun 27, 2025, 05:40 PM EDT
-6.36% (1D)
| Bid | 1.02 |
| Market Cap | 118.65M |
| Revenue (ttm) | 13.34M |
| Net Income (ttm) | -175.88M |
| EPS (ttm) | -1.49 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | -0.93 |
| Analyst | Hold |
| Ask | 1.11 |
| Volume | 2,089,131 |
| Avg. Volume (20D) | 2,095,927 |
| Open | 1.09 |
| Previous Close | 1.10 |
| Day's Range | 1.03 - 1.09 |
| 52-Week Range | 0.66 - 5.92 |
| Beta | 2.23 |
About FATE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FATE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FATE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Fate Therapeutics Inc. is scheduled to release its earnings on Aug 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+21.17%
Fate Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+2.64%
Fate Therapeutics shares are trading higher after the company unveiled its Phase 1 data for FT819 CAR T-cell therapy in systemic lupus erythematosus. Its first three patients showed rapid and sustained b-cell depletion with no dose-limiting toxicities.
1 month ago · seekingalpha.com
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy SectorI've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm. Revisiting FATE after a year, I aim to determ...
